SynthesisDiabetes care2009
Metformin for obesity in children and adolescents: a systematic review.
Synthesis in Diabetes care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.European journal of clinical pharmacology · 2019Pooled it
- Drug interventions for the treatment of obesity in children and adolescents.The Cochrane database of systematic reviews · 2016Pooled it
- Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Cancer prevention research (Philadelphia, Pa.) · 2014 · on this mapPooled it
- Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity.The Journal of clinical endocrinology and metabolism · 2021Trial
- Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial.Nutrition & diabetes · 2016Trial
- Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial.BMC pediatrics · 2014 · on this mapTrial
- Trial
- Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial.Diabetes · 2011 · on this mapTrial
- From Discovery to Innovative Translational Approaches in 80 Years of Fragile X Syndrome Research.Biomedicines · 2025Review
- Longitudinal follow-up of metformin treatment in Fragile X Syndrome.Frontiers in psychology · 2024Article
- Article
- Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK-dependent mechanisms.Journal of cellular and molecular medicine · 2022Review
- Benefits of Physical Activity on Cardiometabolic Diseases in Obese Children and Adolescents.Journal of translational internal medicine · 2022Article
- Is autosomal dominant polycystic kidney disease an early sweet disease?Pediatric nephrology (Berlin, Germany) · 2022Review
- Dicarbonyl stress, protein glycation and the unfolded protein response.Glycoconjugate journal · 2021Review
- The Effects of Anti-obesity Pharmacotherapy Interventions on Psychosocial Factors Among Adolescents with Obesity: a Scoping Review.Current nutrition reports · 2021Article
- Tuning Adipogenic Differentiation in ADSCs by Metformin and Vitamin D: Involvement of miRNAs.International journal of molecular sciences · 2020Article
- Metformin treatment in young children with fragile X syndrome.Molecular genetics & genomic medicine · 2019Article
- Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases.Molecular genetics & genomic medicine · 2019Article
- Targeting cellular metabolism to reduce head and neck cancer growth.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo summarize the efficacy of metformin in reducing BMI and cardiometabolic risk in obese children and adolescents without diabetes. RESEARCH DESIGN AND
methodsWe performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Double-blind RCTs of > or =6 months duration in obese subjects age < or =19 years without diabetes were included. Our primary outcomes of interest include changes in BMI and measures of insulin sensitivity.
resultsFive trials met inclusion criteria (n = 320 individuals). Compared with placebo, metformin reduced BMI by 1.42 kg/m(2) (95% CI 0.83-2.02) and homeostasis model assessment insulin of resistance (HOMA-IR) score by 2.01 (95% CI 0.75-3.26).
conclusionsMetformin appears to be moderately efficacious in reducing BMI and insulin resistance in hyperinsulinemic obese children and adolescents in the short term. Larger, longer-term studies in different populations are needed to establish its role in the treatment of overweight children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.